ORGAPRED selects CYTOQUBE® from Hamamatsu Photonics for personalized oncology research and therapeutic discovery

ORGAPRED, a France-based core facility specializing in Patient-Derived Tumor Organoid (PDTO) research, has selected the CYTOQUBE high-throughput 3D imaging system from Hamamatsu Photonics France to support personalized oncology drug screening and therapeutic discovery. The system enables rapid multi-color analysis of PDTOs and strengthens ORGAPRED’s ability to evaluate treatment efficacy on these models.

The Hamamatsu x ORGAPRED team. From the left: DESMARTIN Guillaume, EMICA Bruno, KOSSAYER Ghenwa, LECOUFLET Lucie, FLORENT Romane, D’ANGELO Jean Marc, Divoux Jordane, WEISWALD Louis-Bastien, POULAIN Laurent, LE GOFF Jérémie. Image Credit: ©Hamamatsu Photonics

Supporting personalized cancer treatment research and drug discovery

ORGAPRED is an innovative core facility dedicated to the production of PDTOs (also called tumoroids) to support personalized medicine and oncology research. Patient tumor samples are used to generate tumoroids, which are cultured for several weeks and distributed into 384-well 

plates for drug testing. The CYTOQUBE system enables rapid 3D multi-color imaging to assess PDTO viability and cell death, providing a comprehensive evaluation of treatment response.

With CYTOQUBE, we can analyze tumoroids in three dimensions across entire plates, much faster than with conventional imaging approaches. This allows us to compare drug responses more efficiently, to support personalized oncology research, and to accelerate the identification of new effective therapeutic strategies.

Dr. Romane Florent, Research Engineer, ORGAPRED

A collaboration developed over time

The relationship between Hamamatsu Photonics France and ORGAPRED began in 2021 and progressed through scientific exchanges, conferences, and technical evaluations. In March 2025, an on-site system evaluation supported ORGAPRED’s funding application and subsequent public tender process, which was awarded in December 2025.

Demonstrated performance advantages

During evaluation, the CYTOQUBE system demonstrated intuitive operation, simplified protocol creation, automated tumoroid segmentation, and clear data visualization. The system performs a 3-color 3D analysis in less than 30 minutes, independent of plate format (96, 384, or 1536 wells).

By comparison, conventional confocal microscopy workflows may require more time due to multi z-stack acquisition.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Hamamatsu Photonics Europe. (2026, April 15). ORGAPRED selects CYTOQUBE® from Hamamatsu Photonics for personalized oncology research and therapeutic discovery. News-Medical. Retrieved on April 15, 2026 from https://www.news-medical.net/news/20260415/ORGAPRED-selects-CYTOQUBEc2ae-from-Hamamatsu-Photonics-for-personalized-oncology-research-and-therapeutic-discovery.aspx.

  • MLA

    Hamamatsu Photonics Europe. "ORGAPRED selects CYTOQUBE® from Hamamatsu Photonics for personalized oncology research and therapeutic discovery". News-Medical. 15 April 2026. <https://www.news-medical.net/news/20260415/ORGAPRED-selects-CYTOQUBEc2ae-from-Hamamatsu-Photonics-for-personalized-oncology-research-and-therapeutic-discovery.aspx>.

  • Chicago

    Hamamatsu Photonics Europe. "ORGAPRED selects CYTOQUBE® from Hamamatsu Photonics for personalized oncology research and therapeutic discovery". News-Medical. https://www.news-medical.net/news/20260415/ORGAPRED-selects-CYTOQUBEc2ae-from-Hamamatsu-Photonics-for-personalized-oncology-research-and-therapeutic-discovery.aspx. (accessed April 15, 2026).

  • Harvard

    Hamamatsu Photonics Europe. 2026. ORGAPRED selects CYTOQUBE® from Hamamatsu Photonics for personalized oncology research and therapeutic discovery. News-Medical, viewed 15 April 2026, https://www.news-medical.net/news/20260415/ORGAPRED-selects-CYTOQUBEc2ae-from-Hamamatsu-Photonics-for-personalized-oncology-research-and-therapeutic-discovery.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Dotphoton and Hamamatsu Photonics are partnering to provide the ultimate raw image compression and address the ever-growing biomedical image data volume